Compare Becton Dickinson and Co (BDX) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Linde PLC — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Linde PLC trades at $490.53 (market cap $227.01B). The key difference: Linde PLC is far larger — about 4.6× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | LIN | |
|---|---|---|
Market Cap | $48.93B | $227.01B |
Sector | Health | Basic Materials |
52-Week High | $185.39 | $546.64 |
52-Week Low | $138.62 | $389.38 |
Enterprise Value | $65.03B | $250.13B |
Dividend Yield | 2.34% | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Linde (LIN) trades at $490.53, up 0.11% on the day, with a bearish technical signal despite strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.50 surpassing expectations. Revenue grew to $34.0B in 2025, with a net income margin of 20.43%. Analysts maintain a strong buy consensus with a $553.60 price target, highlighting robust profitability and dividend growth.
Outlook remains positive due to earnings momentum and sustainability leadership, but risks include elevated valuation multiples and rising debt-to-asset ratio. The stock offers steady income with a $1.60 dividend, yet technical weakness near support at $489 warrants caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
